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Pancreatic cancer afflicts close to 32,000
individuals each year in the United States
and 168,000 worldwide, and nearly all
patients die from the ravages of their dis-
ease. Ductal adenocarcinoma, by far the
most common histologic variant, is also
the most challenging to diagnose and
treat (Yeo et al., 2002). The last decade
has provided several critical insights into
the molecular pathogenesis of early pan-
creatic cancer. Notably, there is now
strong evidence that invasive pancreatic
adenocarcinoma proceeds through a
morphologic spectrum of noninvasive
ductal lesions known as pancreatic
intraepithelial neoplasia (PanIN), and that
histologic progression of these lesions
toward invasive cancer is associated with
the progressive accumulation of
genetic abnormalities (Maitra et al.,
2005). The identification of noninva-
sive precursor lesions of pancreatic
cancer has enormous significance,
since it provides an unprecedented
opportunity for diagnostic and ther-
apeutic interventions at a curable
stage.
Despite the tremendous ad-
vances made in the field of pancre-
atic cancer genetics, there was,
until recently, one remaining “bot-
tleneck” on accelerating research
into this disease, namely, the avail-
ability of a genetically engineered
mouse model that would faithfully
recapitulate the multistage progres-
sion of human pancreatic cancer.
Although the pancreas was one of
the first organs in which tissue-specific
transgenesis was accomplished (Ornitz
et al., 1987), many of the earlier studies
utilized acinar-specific promoters (e.g.,
Elastase) for oncogene targeting. Not
surprisingly, these models of murine
exocrine pancreatic neoplasia reflected
an acinar histogenesis (Sandgren et al.,
1990), quite unlike the ductal adenocar-
cinomas that dominate human disease.
Ironically, oncogene targeting utilizing a
ductal promoter (cytokeratin 19) yielded
only a minimal phenotype of perdicutal
inflammation (Brembeck et al., 2003),
implying that, at least in the mouse pan-
creas, this terminally differentiated com-
partment is unlikely to be the proximate
cell-of-origin for ductal adenocarcinoma.
A quantum leap toward establishing a
phenocopy of the cognate human condi-
tion was made by virtue of targeting to
the endogenous KRAS locus an onco-
genic KRASG12D allele, activated in the
developing pancreas by Cre-mediated
recombination (Hingorani et al., 2003);
notably, Cre was expressed in this model
as a Pdx1 promoter-driven transgene (a
near identical pancreatic phenotype was
produced by KRASG12D activation by Cre
knocked in at the Ptf1-p48 locus). These
mice uniformly develop pancreatic intra-
ductal lesions that mirror the histologic
spectrum of human PanINs, and at a low
frequency, develop invasive, widely
metastatic pancreatic adenocarcinoma.
Pdx1 is a homeodomain protein that is a
critical regulator of early pancreatic
development, as targeted deletion of this
gene during embryogenesis aborts pan-
creatic morphogenesis. The vast majori-
ty of differentiated cell types in the
mature pancreas arise from a common
Pdx1-expressing endocrine/exocrine
precursor; postnatally, expression of
Pdx1 is essentially restricted to the islets
of Langerhans (Song et al., 1999). The
generation of a ductal neoplastic pheno-
type by oncogene targeting using Pdx1
regulatory elements, but not mature aci-
nar- or ductal-specific promoters, sup-
ports the  notion of an undifferentiated
precursor population as the initi   cer.The
identity of this precursor population has
not been discerned, but it either preex-
ists within the adult pancreas, or arises
by “dedifferentiation” of differentiated
elements, consistent with the reported
plasticity of these mature components
(Means et al., 2005).
In this issue of Cancer Cell, Stanger
et al. (2005) utilize a mouse model of tar-
geted PTEN gene deletion to provide
some elegant insights into mecha-
nisms of homeostasis in the pan-
creas, and in the process, generate
a new model of murine preinvasive
and invasive adenocarcinoma. The
PTEN (phosphatase and tensin
homolog deleted on chromosome
10) tumor suppressor gene is fre-
quently deleted or mutated in
human cancers. Germline muta-
tions of PTEN result in a group of
related disorders known as “PTEN
hamartoma tumor syndrome,” char-
acterized by multiple hamartomas
and an increased predisposition to
solid cancers of the breast and thy-
roid. The tumor suppressor function
of the Pten phosphatase is related
to its antagonism of the PI3-K/Akt
signaling pathway. Aberrant activa-
tion of the PI3-K/Akt pathway is extremely
common in many solid cancers, including
pancreatic cancers, and as such can
arise via several mechanisms, including
oncogenic mutations in the activating
components (e.g., PIK3CA or AKT2
genes) or loss of function mutations in the
inhibitory components (e.g., PTEN or the
TSC1/2 genes) (Vivanco and Sawyers,
2002). The Ptenlox/lox mouse model
described in this article has previously
been utilized for tissue-specific gene
deletion in the prostatic and ovarian
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accompanied by loss of differentiated acinar units. Evidence is presented for a centroacinar cell origin of the metaplastic
“neoductules.”These mice also develop invasive pancreatic adenocarcinomas at a low frequency, and provide a unique in
vivo platform for exploring the role of PI3-K/Akt signaling in pancreatic neoplasia.
Figure 1. Model for Pten deletion and ductal metaplasia
Pten-deficient centroacinar cells (green ovals) begin to
proliferate during development. Centroacinar cell
expansion leads to apoptosis of acinar cells (white trian-
gles) due to loss of acinar integrity or survival signals.
Progeny of these centroacinar cells form tubular com-
plexes with mucinous metaplasia. Reproduced with per-
mission from Stanger et al. (2005).
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epithelia, resulting in the full histologic
spectrum of lesions ranging from pre-
neoplasia to metastatic carcinomas
(Dinulescu et al., 2005; Wang et al.,
2003). Thus, given its established pedi-
gree as a tumor suppressor at multiple
anatomic sites, a putative role for Pten in
pancreatic exocrine neoplasia would
seem almost intuitive. Nevertheless, this
study yields novel, and somewhat unex-
pected, information regarding the influ-
ence of the PI3-K/Akt signaling pathway
on the balance of differentiated cell types
in the mature pancreas.
By selectively deleting Pten in Pdx1-
expressing progenitor cells within the
developing pancreas of bitransgenic
Pdx1-Cre; Ptenlox/lox mice, the overwhelm-
ing phenotype to emerge is one of ductal
metaplasia. Beginning at approximately 
3 weeks of age, there is progressive
effacement of acinar structures by “neo-
ductules,” with the metaplastic epithelium
eventually replacing entire lobules.
Symptoms of systemic distress develop
in these mice by approximately 2–3
months, and at necropsy, cystic lesions
that histologically correspond to cystically
dilated ductular complexes are often
observed. Metaplastic ductal epithelium
is no stranger to the world of genetically
engineered mouse models of pancreas
cancer, and in fact, the recent consensus
conference on histologic classification of
murine pancreatic lesions defines “acinar-
ductal-metaplasia” (ADM) as an entity dis-
tinct from murine pancreatic intraepithelial
neoplasia (mPanIN) lesions (Hruban et
al., unpublished data).While ADM is most
prominent in mouse models that rely on
acinar promoters for gene targeting
(Sandgren et al., 1990), such lesions are
at least focally observed in other systems
(e.g., Pdx1-Cre; LSL-KRASG12D mice),
and in certain human disease states
(e.g., chronic pancreatitis). Implicit in the
moniker of ADM is the understanding that
these lesions arise via transdifferentiation
of acinar cells into ductular epithelium
(Means et al., 2005). However, Stanger et
al. (2005) provide a compelling argument
that in the Pdx1-Cre; Ptenlox/lox mice, the
“neoductules” do not arise via acinar-duc-
tal transdifferentiation, but rather from
expansion of an existing centroacinar cell
population with concomitant replacement
of acini. The evidence provided against
acinar-ductal transdifferentiation is more
conclusive than the evidence for cen-
troacinar cell expansion; for example, it is
noted that the neoductular population
expresses the Notch pathway target
gene Hes1, which is also a marker of nor-
mal centroacinar cells (Miyamoto et al.,
2003). In the ductal metaplasia model
proposed by Stanger et al. (Figure 1),
Pten-deficient centroacinar cells begin to
proliferate during development. By a few
weeks of age, centroacinar cell expan-
sion results in apoptosis of acinar cells,
accompanied by formation of tubular
complexes with mucinous metaplasia.
The definitive proof of this model will
require lineage-tracing studies with Hes1
regulatory elements. However, this study
provides the first indication that Pten, and
by extension the PI3-K/Akt pathway,
maintains the balance between various
cell types in the adult pancreas.
In addition to the prominent meta-
plastic phenotype, Pdx1-Cre; Ptenlox/lox
mice develop invasive pancreatic adeno-
carcinomas at a low frequency. The
precise ontogenic relationship between
the metaplastic epithelium and ductal
neoplasia is uncertain. The rapid onset
of metaplasia with accompanying debil-
itation likely offsets the possibility of
developing PanIN lesions with high
penetrance, as observed in the Pdx1-
Cre; KRASG12D mice. Nonetheless, the
occurrence of invasive adenocarcino-
mas in a subset of mice confirms the
importance of the PI3-K/Akt pathway in
the pancreas. In the central nervous 
system, Pten negatively regulates
stem/progenitor cell numbers (Groszer et
al., 2001), and it is tempting to speculate
that loss of Pten function within Pdx1-
expressing compartment of the develop-
ing pancreas results in the persistence of
multipotent progenitor cells susceptible to
neoplastic transformation under appro-
priate conditions. For example, one can
envision the simultaneous targeting of an
oncogenic Kras allele to the putative
Pten-deficient progenitor cell population
as an instance of a highly conducive
genetic environment for inducing neopla-
sia; in fact, similar oncogenic cooperativi-
ty between Pten and Kras results in
metastatic ovarian adenocarcinomas in
mice (Dinulescu et al., 2005). From a
translational perspective, these results
further establish the emerging role of PI3-
K/Akt pathway as a therapeutic target in
established human pancreatic cancers
(Asano et al., 2005). In addition, given the
putative role of Pten dysregulation in the
“primordial” lesions of pancreatic neopla-
sia, the prospect of treating pancreatic
cancer at its earliest stages, or aborting
the disease altogether, might become a
real possibility in predisposed individuals.
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